Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240033/S002

LungFX Device

Lung Bioengineering, Inc. · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP240033/S002

What did the FDA approve?

The FDA database entry P240033/S002 records approval of a post-approval study (PAS) protocol for the LungFX device, submitted on the normal 180 day track with no user fee. The stated purpose is to comply with conditions of approval in the original P240033 order; this supplement does not re-approve the whole system or add an indication. The listed device category describes the original scope: a normothermic preservation system for transplantation of initially unacceptable donor lungs, with product code PHO and applicant Lung Bioengineering, Inc.

The entry does not state the protocol's study design, endpoints, sample size, follow-up duration, or the specific approval conditions it addresses. It also records no safety or effectiveness findings, and the compliance statement is not independent evidence of clinical benefit. The specialty fields list Gastroenterology, Urology, which the supplied text does not explain relative to the lung preservation scope.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240033.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 16, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240033/S002
Regulatory pathway
PMA supplement
Product code
PHO
Decision code
APPR
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.

Product code
PHO
FDA device class
3

For the original device and its historical approval scope, see PMA P240033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240033/S002 received

    Application receipt date recorded by FDA.

  2. P240033/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240033

Product / regulatory recordCompanyPathwayDecision dateSource
Lung Bioengineering, Inc.PMA approvalJun 22, 2026FDA
LungFX DeviceP240033/S001
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code PHO

Product / regulatory recordCompanyPathwayDecision dateSource
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Xvivo Perfusion, Inc.PMA supplementSep 16, 2026FDA
Traferox Technologies, Inc.PMA approvalJul 15, 2026FDA
Xvivo Perfusion, Inc.PMA approvalApr 26, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lung Bioengineering, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records